AU2002359679B2 - Guanidinium transport reagents and conjugates - Google Patents

Guanidinium transport reagents and conjugates Download PDF

Info

Publication number
AU2002359679B2
AU2002359679B2 AU2002359679A AU2002359679A AU2002359679B2 AU 2002359679 B2 AU2002359679 B2 AU 2002359679B2 AU 2002359679 A AU2002359679 A AU 2002359679A AU 2002359679 A AU2002359679 A AU 2002359679A AU 2002359679 B2 AU2002359679 B2 AU 2002359679B2
Authority
AU
Australia
Prior art keywords
compound
group
transport
agent
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002359679A
Other languages
English (en)
Other versions
AU2002359679A1 (en
Inventor
Theodore C. Jessop
Kanaka Pattabiraman
Erin T. Pelkey
Jonathan B. Rothbard
Paul A. Wender
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CellGate Inc
Leland Stanford Junior University
Original Assignee
CellGate Inc
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CellGate Inc, Leland Stanford Junior University filed Critical CellGate Inc
Publication of AU2002359679A1 publication Critical patent/AU2002359679A1/en
Application granted granted Critical
Publication of AU2002359679B2 publication Critical patent/AU2002359679B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002359679A 2001-12-11 2002-12-11 Guanidinium transport reagents and conjugates Ceased AU2002359679B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33969601P 2001-12-11 2001-12-11
US60/339,696 2001-12-11
PCT/US2002/039698 WO2003049772A2 (en) 2001-12-11 2002-12-11 Guanidinium transport reagents and conjugates

Publications (2)

Publication Number Publication Date
AU2002359679A1 AU2002359679A1 (en) 2003-06-23
AU2002359679B2 true AU2002359679B2 (en) 2009-01-08

Family

ID=23330202

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002359679A Ceased AU2002359679B2 (en) 2001-12-11 2002-12-11 Guanidinium transport reagents and conjugates

Country Status (7)

Country Link
US (1) US7169814B2 (https=)
EP (1) EP1461084A2 (https=)
JP (1) JP2005538035A (https=)
AU (1) AU2002359679B2 (https=)
CA (1) CA2469336C (https=)
MX (1) MXPA04005611A (https=)
WO (1) WO2003049772A2 (https=)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5610659B2 (ja) 2000-07-21 2014-10-22 ルバンス セラピュティックス インク．Ｒｅｖａｎｃｅ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 多成分生物学的輸送システム
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US6969514B2 (en) * 2003-02-05 2005-11-29 Soll David B Method for treating elevated intraocular pressure, including glaucoma
US7538084B2 (en) 2003-03-17 2009-05-26 Amr Technology, Inc. Cyclosporins
US7468418B2 (en) * 2003-04-29 2008-12-23 Avi Biopharma., Inc. Compositions for enhancing transport of molecules into cells
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
BRPI0508410B8 (pt) * 2004-03-03 2021-05-25 Revance Therapeutics Inc composições e métodos para a aplicação tópica e liberação transdérmica de toxinas botulínicas
JP2007527431A (ja) * 2004-03-03 2007-09-27 ルバンス セラピュティックス 局所的診断及び治療用の輸送のための組成物及び方法
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
GB0413613D0 (en) * 2004-06-17 2004-07-21 Univ London Small molecule carriers
WO2006010084A2 (en) * 2004-07-06 2006-01-26 Segev Laboratories Limited A system for delivering therapeutic agents into living cells and cell nuclei
US8680062B2 (en) 2004-07-06 2014-03-25 Deliversir Ltd. System for delivering therapeutic agents into living cells and cells nuclei
JP2008514701A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
JP2008514702A (ja) 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド 新規シクロスポリン類似体およびそれらの薬学的使用
JP2008515886A (ja) 2004-10-06 2008-05-15 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキンおよびそれらの医用薬剤としての有用性
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
MX2007010674A (es) * 2005-03-03 2007-11-08 Revance Therapeutics Inc Composiciones y metodos para la aplicacion topica y el suministro transdermico de un oligopeptido.
GB2427360A (en) * 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
WO2007038172A2 (en) * 2005-09-23 2007-04-05 Nitto Denko Corporation Guanidinium carriers
WO2007038171A2 (en) 2005-09-23 2007-04-05 Nitto Denko Corporation Peptide nucleic acid based guanidinium compounds
US7745392B2 (en) 2005-09-23 2010-06-29 Nitto Denko Corporation Multi-valent guanidinium compounds for enhancing molecular translocation across cellular membranes and epithelial tissues
CN103126971A (zh) * 2005-11-17 2013-06-05 雷文斯治疗公司 减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法
JP5572318B2 (ja) * 2005-12-30 2014-08-13 ルバンス セラピュティックス インク． 局所投与用アルギニンヘテロマー
US7696165B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
WO2008008872A2 (en) * 2006-07-14 2008-01-17 Wisconsin Alumni Research Foundation Adsorptive membranes for trapping viruses
EP2561891A3 (en) * 2006-09-27 2013-03-06 Paolo Botti Means and methods of enhancing delivery to biological systems
EP1905454A1 (en) * 2006-09-27 2008-04-02 Paolo Botti Formulations comprising cyclic compounds
BRPI0720729A2 (pt) * 2006-12-29 2014-04-08 Revance Therapeutics Inc Moléculas de transporte que utilizam polipeptídeos hiv-tat de sequência inversa.
CN102988995A (zh) * 2006-12-29 2013-03-27 雷文斯治疗公司 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法
US9260476B2 (en) 2007-02-23 2016-02-16 The Research Foundation For The State University Of New York RNA targeting compounds and methods for making and using same
EP2591795B1 (en) * 2007-02-23 2018-02-28 The Research Foundation Of State University Of New York RNA targeting compounds and methods for making and using same
EP2144633B1 (en) * 2007-04-23 2014-07-16 Deliversir Ltd A system for delivering therapeutic agents into living cells and cells nuclei
US9156865B2 (en) 2007-04-23 2015-10-13 Deliversir Ltd System for delivering therapeutic agents into living cells and cells nuclei
US9556210B2 (en) 2007-04-23 2017-01-31 Sabag-Rfa Ltd. System for delivering therapeutic agents into living cells and cells nuclei
WO2009005793A2 (en) * 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CA2694046C (en) * 2007-07-26 2023-09-12 Revance Therapeutics, Inc. Cationic peptides and compositions thereof
US7842762B2 (en) * 2007-08-08 2010-11-30 Ppg Industries Ohio, Inc. Electrodepositable coating composition containing a cyclic guanidine
US20110160146A1 (en) * 2008-02-07 2011-06-30 National Institute of Health (NIH) Conjungation of Small Molecules to Octaarginine Transporters for Overcoming Multi-Drug Resistance
WO2010077732A2 (en) * 2008-12-09 2010-07-08 Aether Medical Llc Implantable analgesic
US20100311671A1 (en) * 2009-03-25 2010-12-09 Kai Pharmaceuticals Transdermal delivery of pkc modulatory peptides through microporated skin
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
EP2563381B1 (en) 2010-04-27 2017-08-09 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
CN103097524B (zh) 2010-04-28 2016-08-03 Atyr医药公司 与丙氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
EP2563383B1 (en) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
AU2011248227B2 (en) 2010-05-03 2016-12-01 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
ES2668207T3 (es) 2010-05-03 2018-05-17 Atyr Pharma, Inc. Descubrimiento innovador de composiciones terapéuticas, de diagnóstico y de anticuerpos relacionadas con fragmentos de proteínas de metionil-ARNt sintetasas
CN103096925A (zh) 2010-05-03 2013-05-08 Atyr医药公司 与精氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
JP6008844B2 (ja) 2010-05-04 2016-10-19 エータイアー ファーマ， インコーポレイテッド ｐ３８ＭＵＬＴＩ−ｔＲＮＡ合成酵素複合体のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
EP2568996B1 (en) 2010-05-14 2017-10-04 aTyr Pharma, Inc. Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
CN103096913B (zh) 2010-05-27 2017-07-18 Atyr 医药公司 与谷氨酰胺酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
CA2800281C (en) 2010-06-01 2021-01-12 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of lysyl-trna synthetases
AU2011289831C1 (en) 2010-07-12 2017-06-15 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-tRNA synthetases
CN103108650A (zh) 2010-08-25 2013-05-15 Atyr医药公司 与酪氨酰-tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的创新发现
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US9902957B2 (en) 2011-09-06 2018-02-27 The Board Of Trustees Of The Leland Stanford Junior University Amphipathic co-oligomers for the delivery of siRNA
US9816066B2 (en) 2012-04-24 2017-11-14 The Regents Of The University Of California Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters
CN102863357B (zh) * 2012-09-20 2014-01-01 华中农业大学 具有植物生长调节活性的化合物及其制备方法
AU2013336237A1 (en) 2012-10-22 2015-06-11 Sabag-Rfa Ltd A system for delivering therapeutic agents into living cells and cells nuclei
MX370929B (es) 2012-10-28 2020-01-08 Revance Therapeutics Inc Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
US9068089B2 (en) 2013-03-15 2015-06-30 Ppg Industries Ohio, Inc. Phenolic admix for electrodepositable coating composition containing a cyclic guanidine
US9688874B2 (en) 2013-10-25 2017-06-27 Ppg Industries Ohio, Inc. Method of making a bicyclic guanidine-cured acrylic coating
JP6807831B2 (ja) 2014-05-21 2021-01-06 エントラーダ セラピューティクス，インコーポレイテッド 細胞膜透過性ペプチド、並びにこの作製方法及び使用方法
US10815276B2 (en) 2014-05-21 2020-10-27 Entrada Therapeutics, Inc. Cell penetrating peptides and methods of making and using thereof
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US10383912B2 (en) * 2014-08-18 2019-08-20 Washington State University Tunable pH-sensitive linker for controlled drug release
WO2016033368A1 (en) 2014-08-27 2016-03-03 Ohio State Innovation Foundation Improved peptidyl calcineurin inhibitors
US9854806B2 (en) 2015-05-19 2018-01-02 International Business Machines Corporation Antimicrobial guanidinium and thiouronium functionalized polymers
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
CN115252807A (zh) * 2016-07-27 2022-11-01 利兰斯坦福初级大学董事会 用于核酸递送的解体型细胞穿透性复合物
KR102810425B1 (ko) 2016-12-19 2025-05-21 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
PH12019502594A1 (en) 2017-05-19 2020-10-26 Lunella Biotech Inc Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
CA3078504A1 (en) 2017-10-04 2019-04-11 Ohio State Innovation Foundation Bicyclic peptidyl inhibitors
WO2019108729A1 (en) 2017-12-01 2019-06-06 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
WO2019148195A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Cyclic peptidyl inhibitors of cal-pdz binding domain
WO2019148194A2 (en) 2018-01-29 2019-08-01 Ohio State Innovation Foundation Peptidyl inhibitors of calcineurin-nfat interaction
WO2019165183A1 (en) 2018-02-22 2019-08-29 Entrada Therapeutics, Inc. Compositions and methods for treating mitochondrial neurogastrointestinal encephalopathy
EP3775052B1 (en) 2018-03-30 2024-06-05 Becton, Dickinson and Company Water-soluble polymeric dyes having pendant chromophores
US11987647B2 (en) 2018-05-09 2024-05-21 Ohio State Innovation Foundation Cyclic cell-penetrating peptides with one or more hydrophobic residues
KR102167755B1 (ko) 2018-05-23 2020-10-19 주식회사 큐어바이오 단편화된 grs 폴리펩타이드, 이의 변이체 및 이들의 용도
MX2021002833A (es) 2018-09-27 2021-05-27 Biophysics Pharma Inc Sistema de suministro de farmaco transdermico.
US10953039B2 (en) 2018-09-27 2021-03-23 International Business Machines Corporation Utilizing polymers and antibiotics to enhance antimicrobial activity and inhibit antibiotic resistance
US12246098B2 (en) 2018-09-27 2025-03-11 BioPhysics Pharma, Inc. Trans-epithelial membrane drug delivery system
US11931416B2 (en) 2019-02-01 2024-03-19 The Board Of Trustees Of The Leland Stanford Junior University Immolative cell-penetrating complexes for nucleic acid delivery to the lung
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
KR20250133471A (ko) 2020-02-18 2025-09-05 길리애드 사이언시즈, 인코포레이티드 항바이러스 화합물
TWI883391B (zh) 2020-02-18 2025-05-11 美商基利科學股份有限公司 抗病毒化合物
CA3184089A1 (en) * 2020-07-02 2022-01-06 University Of Houston System Compounds for drug delivery across blood-brain barrier
AU2021386370A1 (en) 2020-11-24 2023-06-22 Lyell Immunopharma, Inc. Methods for making, compositions comprising, and methods of using rejuvenated t cells
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
AU2022328698B2 (en) 2021-08-18 2025-02-20 Gilead Sciences, Inc. Phospholipid compounds and methods of making and using the same
EP4155349A1 (en) 2021-09-24 2023-03-29 Becton, Dickinson and Company Water-soluble yellow green absorbing dyes
WO2025250872A1 (en) * 2024-05-31 2025-12-04 Florida Atlantic University Board Of Trustees Antibody complementary determining region of heavy chain 3 mimics and methods of use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4004074A (en) * 1968-06-18 1977-01-18 Colgate-Palmolive Company Highly substantive sunscreening agents
DE3310337A1 (de) * 1983-03-22 1984-09-27 Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg Verfahren zur durchfuehrung von hybridisierungsreaktionen
US5723496A (en) * 1991-03-05 1998-03-03 The Regents Of University Of California Method for prevention and treatment of harmful effects of intracellular acidosis
JP2651317B2 (ja) * 1992-06-18 1997-09-10 扶桑薬品工業株式会社 核酸の検出法
US6251433B1 (en) * 1996-08-13 2001-06-26 Chiron Corporation Polycationic polymers
CN1263473A (zh) * 1997-05-21 2000-08-16 利兰·斯坦福青年大学托管委员会 增加跨生物膜转运的组合物和方法
AUPP584298A0 (en) * 1998-09-14 1998-10-08 Starpharma Limited Antimicrobial and antiparasitic agents
IL127773A0 (en) * 1998-12-28 1999-10-28 Yeda Res & Dev Saccharide conjugates and pharmaceutical compositions comprising them
US6593466B1 (en) * 1999-07-07 2003-07-15 Isis Pharmaceuticals, Inc. Guanidinium functionalized nucleotides and precursors thereof
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6593292B1 (en) * 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) * 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
DE60233137D1 (de) * 2001-02-16 2009-09-10 Univ R Transporter mit beabstandeten arginin-teilchen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Wender Paul et al, PNAS, Vol 97, no 24, 21 November 2000. *

Also Published As

Publication number Publication date
CA2469336A1 (en) 2003-06-19
US7169814B2 (en) 2007-01-30
US20040161405A9 (en) 2004-08-19
AU2002359679A1 (en) 2003-06-23
WO2003049772A2 (en) 2003-06-19
US20030185788A1 (en) 2003-10-02
EP1461084A2 (en) 2004-09-29
MXPA04005611A (es) 2005-04-19
WO2003049772A3 (en) 2003-11-20
CA2469336C (en) 2013-06-11
JP2005538035A (ja) 2005-12-15

Similar Documents

Publication Publication Date Title
AU2002359679B2 (en) Guanidinium transport reagents and conjugates
ES2210761T3 (es) Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
AU2002306500B2 (en) Transporters comprising spaced arginine moieties
US7935816B2 (en) Molecular transporter compositions comprising dendrimeric oligoguanidine with a triazine core that facilitate delivery into cells in vivo
ES2834916T3 (es) Agente terapéutico dirigido de dendrímero de polilisina
EP1466627A1 (en) Polyglutamate camptothecin conjugates
JP2006507322A (ja) 多重自己脱離放出スペーサーとして構築されたプロドラッグ
AU2002306500A1 (en) Transporters comprising spaced arginine moieties
EP1263469A1 (en) Compositions and methods for enhancing drug delivery across biological membranes and tissues
CA2381425A1 (en) Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
JP2011523415A (ja) 新規な二重標的化抗腫瘍複合体
Lu et al. Preparation, characterization, and in vitro efficacy of O-carboxymethyl chitosan conjugate of melphalan
EP1304122A2 (en) Composition and method for enhancing transport across biological membrane
CZ406699A3 (cs) Farmaceutický prostředek a způsob zvýšení transportu vybraných sloučenin přes biologickou membránu
MXPA99010704A (en) Composition and method for enhancing transport across biological membranes
HK1155363A (en) Novel dual targeting antitumoural conjugates
HK1070570A (en) Polyglutamate camptothecin conjugates

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired